MDxHealth SA (0O8G.L)
| Chiusura precedente | 0,6950 |
| Aperto | 0,6920 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,6920 - 0,6920 |
| Intervallo di 52 settimane | 0,6920 - 0,6920 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 382.613 |
| Beta (5 anni mensile) | 0,91 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2150 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
MDxHealth Reports Half Year 2022 Results
NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are excited to report strong operating results for the first half of 2022, couple
- GlobeNewswire
Mdxhealth's New Share Capital Amount and New Number of Shares
NEWS RELEASE - REGULATED INFORMATIONAugust 19, 2022, 4:00 PM EDT / 22:00 CET Mdxhealth's New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM – August 19, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulate
- GlobeNewswire
Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results
NEWS RELEASE – INSIDE AND REGULATED INFORMATIONAugust 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results Solidifies leadership in the precision diagnostics urology marketProvides the most comprehensive menu of advanced molecular tests for urology in prostate cancerEnhances scale with best-in-class commercial channel into urology communityExact Sciences to take portion of initial payment i
